TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy.

Autor: McNerney KO; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Karageorgos S; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Ferry GM; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Wolpaw AJ; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.; The Wistar Institute, Philadelphia, PA., Burudpakdee C; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Khurana P; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Toland CN; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Vemu R; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Vu A; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Hogarty MD; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Bassiri H; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2022 May 24; Vol. 11 (1), pp. 2075204. Date of Electronic Publication: 2022 May 24 (Print Publication: 2022).